VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

Dung T. Le, MD
Published: Friday, Jun 05, 2015



Dung T. Le, MD, assistant professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Le discusses a study that examined the PD-1 blockade of tumors with mismatch repair deficiency. These specific tumors have mutations that could potentially be recognizable by the immune system, she says.

The study included three cohorts: colorectal cancer tumors with mismatch repair deficiency, colorectal cancer tumors with mismatch repair proficiency, and any tumor type with mismatch repair deficiency. Researchers saw that responses were restricted to mismatch repair deficiency, with a 62% response rate in the cohort of patients with CRC. The cohort with mismatch repair proficiency had a 0% response rate, while the third cohort with any tumor type had a 16% response rate. These were durable responses, Le says.


Dung T. Le, MD, assistant professor of oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Le discusses a study that examined the PD-1 blockade of tumors with mismatch repair deficiency. These specific tumors have mutations that could potentially be recognizable by the immune system, she says.

The study included three cohorts: colorectal cancer tumors with mismatch repair deficiency, colorectal cancer tumors with mismatch repair proficiency, and any tumor type with mismatch repair deficiency. Researchers saw that responses were restricted to mismatch repair deficiency, with a 62% response rate in the cohort of patients with CRC. The cohort with mismatch repair proficiency had a 0% response rate, while the third cohort with any tumor type had a 16% response rate. These were durable responses, Le says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x